Farxiga Data Change Heart Failure Treatment Outlook
DAPA-HF data on AstraZeneca’s SGLT-2 inhibitor dapagliflozin as a treatment for heart failure in both diabetics and non-diabetics won spontaneous applause at ESC.
You may also be interested in...
Biopharmaceuticals President Ruud Dobber talked to Scrip about the launches of Lokelma and roxadustat in kidney disease, building with a high bar in cardiovascular disease and expanding in cell and gene therapy.
The latest drug development news and highlights from our US FDA Performance Tracker.
AstraZeneca has got off to a strong start in 2020, with the FDA granting a fast review for its diabetes drug Farxiga in heart failure and China approving Lokelma for hyperkalemia.